Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242001 | 0.83 | THRB (0.41) | THRBTHRAHPGDTSHRCYP1A2 | |
| SCHEMBL3248628 | 0.81 | THRA (0.44) | THRBTHRAHPGDTSHRGRM2 | |
| SCHEMBL16543395 | 0.78 | ALDH1A1 (0.33) | THRBTSHRCYP1A2GRM2GRM3 | |
| SCHEMBL17545782 | 0.78 | EPHX1 (0.34) | HPGDCYP1A2GRM2GRM3HSD11B1 | |
| SCHEMBL1108022 | 0.77 | THRB (0.44) | THRBTHRAHPGDTSHRALDH1A1 | |
| SCHEMBL16682453 | 0.76 | FKBP1A (0.39) | CYP1A2GRM2GRM3HSD11B1EPHX1 | |
| SCHEMBL28036028 | 0.76 | EPHX1 (0.36) | THRBTHRAHPGDTSHRCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL7209197 | 0.75 | THRB (0.43) | THRBHPGDTSHRALDH1A1 | |
| SCHEMBL26179016 | 0.75 | EPHX1 (0.33) | CYP1A2GRM2GRM3HSD11B1EPHX1 | |
| SCHEMBL20579982 | 0.75 | LMNA (0.33) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745658-B2 | Process for preparing tertiary alkyl esters of (meth)acrylic acid having at least 4 carbon atoms in the alkyl radical | BASF SE (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20090023947-A1 | PROCESS FOR PREPARING TERTIARY ALKYL ESTERS OF (METH) ACRYLIC ACID HAVING AT LEAST 4 CARBON ATOMS IN THE ALKYL RADICAL | BASF SE (DE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023947-A1 | PROCESS FOR PREPARING TERTIARY ALKYL ESTERS OF (METH) ACRYLIC ACID HAVING AT LEAST 4 CARBON ATOMS IN THE ALKYL RADICAL | ACSL3, ACSL1, ACSL4 | THRB 1523/4885THRA 347/4885HPGD 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.